AT-100

BIOLOGICAL2 trials

Sponsors

Airway Therapeutics, Inc.

Conditions

Bronchopulmonary DysplasiaCOVID-19Undefined

Phase 1

A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia

TerminatedNCT04659122

Airway Therapeutics, Inc.COVID-19, Undefined

Start: 2021-08-17End: 2023-02-23Updated: 2023-08-14

A Clinical Safety Study of AT-100 (rhSP-D) in Preterm Neonates at High Risk for Bronchopulmonary Dysplasia (BPD)

CompletedNCT04662151

Airway Therapeutics, Inc.Bronchopulmonary Dysplasia

Start: 2021-09-01End: 2024-05-29Updated: 2024-07-03

Related Papers

A phase 1b randomized, multicenter, dose determination trial of zelpultide alfa (recombinant human surfactant protein D) in preterm neonates at high risk of developing bronchopulmonary dysplasia

Frontiers in Pediatrics2025-09-12